Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Kawamura, Yusuke; Arase, Yasuji; Ikeda, Kenji; Seko, Yuya; Imai, Norihiro; Hosaka, Tetsuya; Kobayashi, Masahiro; Saitoh, Satoshi; Sezaki, Hitomi; Akuta, Norio; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Ohmoto, Yuki; Amakawa, Kazuhisa; Tsuji, Hiroshi; Kumada, Hiromitsu

doi:10.1038/ajg.2011.327

Cited by 240 publications

(229 citation statements)

References 49 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…The presence of thrombocytopenia in HCC patients probably reflects the severity of the portal hypertension which is secondary to the cirrhosis in which HCC usually develops, as has been noted previously [11][12][13][14][15] . To our knowledge, an association between thrombocytopenia and HCC size has not previously been reported.…”

Section: Discussionmentioning

confidence: 74%

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 74%

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

2012

View full text Add to dashboard Cite

show abstract

“…A low HCC incidence of 0.25% was observed in a retrospective cohort study in a large sample of NAFLD patients diagnosed by ultrasound (16 of 6,508 NAFLD patients) [25] (HR 8.20, 95% CI 1.09-9.50, p=0.035) were independent risk factors for HCC. Hepatocellular carcinoma was associated with signi cant brosis assessed by the AST to platelet ratio index (APRI) (equivalent to stage 3-4 NASH, HR 25.03, 95% CI 9.02-69.52, p<0.001) but not by the BARD score [25].…”

Section: Incidence Ratesmentioning

confidence: 93%

“…Hepatocellular carcinoma was associated with signi cant brosis assessed by the AST to platelet ratio index (APRI) (equivalent to stage 3-4 NASH, HR 25.03, 95% CI 9.02-69.52, p<0.001) but not by the BARD score [25].…”

Section: Incidence Ratesmentioning

confidence: 99%

Non-invasive Biomarkers in Non-Alcoholic Steatohepatitisinduced Hepatocellular Carcinoma

Voiculescu

Nanau

Neuman

2014

JGLD

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is by far the most common form of chronic liver disease worldwide, affecting adults as well as children. Under the term of NAFLD there is a wide spectrum of diseases ranging from simple steatosis to the non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Several mechanisms have been described to influence the progression of the disease from the benign NAFL to the aggressive NASH. The imbalance between pro- and anti-oxidant mechanisms and between pro- and anti-inflammatory cytokines is thought to play a pivotal role in the pathogenesis of NAFLD and disease progression toward NASH and fibrosis. The present review intends to look at some of the mechanistic biomarkers to be employed in establishing an early diagnosis in HCC derived from NASH.Abbreviations: ANGPT: angiopoietin-2; AFP: α-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: confidence interval; COL: collagen; DCP: des-carboxyprothrombin; γGT: gamma glutamyl transpeptidase; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HR: hazard ratio; ITG: integrin; LAM: laminin collagen genes; MMP: matrix metalloproteinase; MS: metabolic syndrome; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; PDGFRA: platelet derived growth factor receptor-α

show abstract

“…El-Serag és mtsai szerint a diabetes 10 év alatt kétszeresre növeli meg a HCC kockázatát [31], míg japán szerzők azt közölték, hogy NAFLD-betegeknél diabetes esetén ez a kockázat több mint háromszoros [32].…”

Section: Diabetesunclassified

“…A betegségspecifikus mortalitás legerősebb prediktorának a fibrosis bizonyult [15]. Az előrehaladott fibrosisra/cirrhosisra utaló thrombocytopenia (<150 000 G/l) is magas HCC-kockázatot (HR: 7,14) képvisel NASH-betegekben [32]. Egyébként amíg NASH-cirrhosisban évente 2,6%-ban, HCV-cirrhosisban 4,0%-ban alakul ki májrák [33].…”

Section: Fibrosisunclassified

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Pár

2016

Orvosi Hetilap

View full text Add to dashboard Cite

Az utolsó évtizedben a fejlett országokban a nem alkoholos zsírmáj lett a leggyakrabban diagnosztizált krónikus májbetegség. Ugyanakkor e kórképnek, de különösen súlyosabb formájának, a nem alkoholos steatohepatitisnek a szerepe bizonyított a hepatocellularis carcinoma gyakoriságának drámai megnövekedésében. A fő kockázati tényezők a genetikai prediszpozíció mellett az obesitas és a diabetes, valamint a kórfolyamatban gyakran fibrosishoz vezető alacsony fokú krónikus gyulladás. A patogenezisben a szabad zsírsavak és citokinek, a lipotoxicitás, az inzulinrezisztencia, a mikro-RNS-diszreguláció és a bél-baktériumflóra megváltozása kulcsfontosságú. A nem alkoholos zsírmáj kezelése -obesitasban a testsúlycsökkentés és fizikai aktivitás, diabetesben a metformin, dyslipidaemiában a statinok és új lehetőségként az obetikólsav -e betegség következményeként kialakuló hepatocellularis carcinoma prevenció-ját is szolgálhatja. Orv. Hetil., 2016, 157(25), 987-994.Kulcsszavak: nem alkoholos zsírmáj, nem alkoholos steatohepatitis, hepatocellularis carcinoma, genetika, citokinek, inzulinrezisztencia, mikro-RNS, bél-baktériumflóra, diagnózis, szűrés, terápia, obetikólsav, daganatprevenció Non-alcoholic fatty liver disease and hepatocellular carcinoma -2016In the past decade non-alcoholic liver disease became the most frequently diagnosed liver disease in developed countries. At the same time, the dramatic rise in the incidence of hepatocellular carcinoma is attributed to this common metabolic disorder, and mainly to its severe form, non-alcoholic steatohepatitis. The risk factors of these associated diseases are genetic predisposition, obesity and diabetes as well as chronic low grade necro-infammation, which often leads to liver fibrosis. Free fatty acids, cytokines, lipotoxicity, insulin resistance, microRNS dysregulation and alteration in intestinal microbiota play a pivotal role in the pathogenesis. Treatment of non-alcoholic fatty liver disease -weight reduction and physical exercise in obesity, metformin in diabetes, statins in dyslipidemia and, as a new option, obeticholic acid -may diminish the risk of the hepatocellular carcinoma related to this metabolic disease.Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatocellular carcinoma, genetics, cytokines, insulin resistance, microRNA, intestinal microbiota, diagnosis, surveillance, treatment, obeticholic acid, cancer prevention Rövidítések ALP (GPT) = alanin-aminotranszferáz; AMPK = adenozinmonofoszfát-aktivált proteinkináz; BMI = testtömegindex; CDA = chenodezoxikólsav; DNS = dezoxiribonukleinsav; FFA = szabad zsírsav; FGF = fibroblastnövekedési faktor; HBV = hepatitis B-vírus; HCC = hepatocellularis carcinoma; HCV = hepatitis C-vírus; HR = hazard ratio; HSC = hepaticus csillag-(stellatum) sejt; IL = interleukin; IR = inzulinrezisztencia; IRS-1 = inzulinreceptor-szubsztrát-1; KS = Kupffer-sejt; LSP = lipopoliszacharida; MAPK = mitogénaktivált proteinkináz; miR = mikro-RNS; MMP = metalloproteináz; NAFLD = nem alkoholos zsírmáj; NASH = nem al...

show abstract

Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Cited by 240 publications

References 49 publications

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

Non-invasive Biomarkers in Non-Alcoholic Steatohepatitisinduced Hepatocellular Carcinoma

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Contact Info

Product

Resources

About